Skip to main content
رجوع
IMNM logo

Immunome, Inc.

جودة البيانات: 100%
IMNM
NASDAQ Healthcare Biotechnology
KWD 20.75
▲ KWD 0.74 (3.70%)
القيمة السوقية: 1.82B
نطاق اليوم
KWD 20.15 KWD 21.00
نطاق 52 أسبوعًا
KWD 5.15 KWD 27.65
حجم التداول
1,197,014
متوسط 50 يوم / 200 يوم
KWD 22.70 / KWD 15.69
الإغلاق السابق
KWD 20.01

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -8.6 0.4
P/B 2.9 2.9
ROE % -52.1 3.7
Net Margin % -3060.0 3.9
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 36.830 +77.5%
Low: KWD 32.000 High: KWD 40.000
ربحية السهم المستقبلية
-KWD 2.405
الإيرادات المقدّرة
4.4 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.356
-KWD 0.142 – KWD 3.693
620 M 6
FY2029 -KWD 0.059
-KWD 0.160 – KWD 0.006
400 M 6
FY2028 -KWD 1.178
-KWD 2.857 – -KWD 0.478
240 M 8

النقاط الرئيسية

Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -200.60M
PEG of 0.17 suggests growth is underpriced
Capital intensive — 139.53% of revenue goes to capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-23.23%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-52.09%
ROIC-25.16%
Net Margin-3059.99%
Op. Margin-3084.76%

الأمان

Debt / Equity
0.01
Current Ratio14.69
Interest Coverage0.00

التقييم

P/E Ratio
-8.58
P/B Ratio2.87
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -23.23% Revenue Growth (3Y) -29.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6.94M Net Income (TTM) -212.39M
ROE -52.09% ROA -31.09%
Gross Margin 57.43% Operating Margin -3084.76%
Net Margin -3059.99% Free Cash Flow (TTM) -200.60M
ROIC -25.16% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 14.69
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -8.58 P/B Ratio 2.87
P/S Ratio 262.66 PEG Ratio 0.17
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.82B Enterprise Value 1.17B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.94M 9.04M 14.02M 0.0 0.0
Net Income -212.39M -292.96M -106.81M -36.90M -24.71M
EPS (Diluted) -2.43 -5.00 -5.38 -3.09 -2.14
Gross Profit 3.99M 9.04M 14.02M 0.0 0.0
Operating Income -214.11M -305.80M -109.53M -36.90M -25.20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 683.19M 240.24M 148.54M 24.05M 57.93M
Total Liabilities 48.85M 59.08M 28.66M 7.39M 9.74M
Shareholders' Equity 634.34M 181.17M 119.88M 16.65M 48.19M
Total Debt 3.86M 4.83M 1.65M 291,000.0 317,000.0
Cash & Equivalents 653.48M 143.35M 98.68M 20.32M 49.23M
Current Assets 660.78M 221.34M 144.70M 22.65M 56.64M
Current Liabilities 44.99M 54.31M 21.83M 7.33M 9.73M